Global Anti-CD47 Antibody Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Anti-CD47 Antibody: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-CD47 Antibody Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market Segmentation by Application
1.3.1 Global Anti-CD47 Antibody Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-CD47 Antibody Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-CD47 Antibody Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Anti-CD47 Antibody Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Anti-CD47 Antibody Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Monoclonal Antibody Market Size by Players
3.3.2 Polyclonal Antibody Market Size by Players
3.4 Global Anti-CD47 Antibody Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-CD47 Antibody Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-CD47 Antibody Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Anti-CD47 Antibody Market Size by Type (2020-2031)
6.4 North America Anti-CD47 Antibody Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-CD47 Antibody Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Anti-CD47 Antibody Market Size by Type (2020-2031)
7.4 Europe Anti-CD47 Antibody Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-CD47 Antibody Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Anti-CD47 Antibody Market Size by Type (2020-2031)
8.4 Asia-Pacific Anti-CD47 Antibody Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Anti-CD47 Antibody Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Anti-CD47 Antibody Market Size by Type (2020-2031)
9.4 Central and South America Anti-CD47 Antibody Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-CD47 Antibody Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Anti-CD47 Antibody Market Size by Type (2020-2031)
10.4 Middle East and Africa Anti-CD47 Antibody Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-CD47 Antibody Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 BosterBio
11.1.1 BosterBio Corporation Information
11.1.2 BosterBio Business Overview
11.1.3 BosterBio Anti-CD47 Antibody Product Features and Attributes
11.1.4 BosterBio Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.1.5 BosterBio Anti-CD47 Antibody Revenue by Product in 2024
11.1.6 BosterBio Anti-CD47 Antibody Revenue by Application in 2024
11.1.7 BosterBio Anti-CD47 Antibody Revenue by Geographic Area in 2024
11.1.8 BosterBio Anti-CD47 Antibody SWOT Analysis
11.1.9 BosterBio Recent Developments
11.2 Leinco Technologies
11.2.1 Leinco Technologies Corporation Information
11.2.2 Leinco Technologies Business Overview
11.2.3 Leinco Technologies Anti-CD47 Antibody Product Features and Attributes
11.2.4 Leinco Technologies Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.2.5 Leinco Technologies Anti-CD47 Antibody Revenue by Product in 2024
11.2.6 Leinco Technologies Anti-CD47 Antibody Revenue by Application in 2024
11.2.7 Leinco Technologies Anti-CD47 Antibody Revenue by Geographic Area in 2024
11.2.8 Leinco Technologies Anti-CD47 Antibody SWOT Analysis
11.2.9 Leinco Technologies Recent Developments
11.3 Bioss
11.3.1 Bioss Corporation Information
11.3.2 Bioss Business Overview
11.3.3 Bioss Anti-CD47 Antibody Product Features and Attributes
11.3.4 Bioss Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.3.5 Bioss Anti-CD47 Antibody Revenue by Product in 2024
11.3.6 Bioss Anti-CD47 Antibody Revenue by Application in 2024
11.3.7 Bioss Anti-CD47 Antibody Revenue by Geographic Area in 2024
11.3.8 Bioss Anti-CD47 Antibody SWOT Analysis
11.3.9 Bioss Recent Developments
11.4 Novus Biologicals
11.4.1 Novus Biologicals Corporation Information
11.4.2 Novus Biologicals Business Overview
11.4.3 Novus Biologicals Anti-CD47 Antibody Product Features and Attributes
11.4.4 Novus Biologicals Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.4.5 Novus Biologicals Anti-CD47 Antibody Revenue by Product in 2024
11.4.6 Novus Biologicals Anti-CD47 Antibody Revenue by Application in 2024
11.4.7 Novus Biologicals Anti-CD47 Antibody Revenue by Geographic Area in 2024
11.4.8 Novus Biologicals Anti-CD47 Antibody SWOT Analysis
11.4.9 Novus Biologicals Recent Developments
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Corporation Information
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Anti-CD47 Antibody Product Features and Attributes
11.5.4 Thermo Fisher Scientific Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.5.5 Thermo Fisher Scientific Anti-CD47 Antibody Revenue by Product in 2024
11.5.6 Thermo Fisher Scientific Anti-CD47 Antibody Revenue by Application in 2024
11.5.7 Thermo Fisher Scientific Anti-CD47 Antibody Revenue by Geographic Area in 2024
11.5.8 Thermo Fisher Scientific Anti-CD47 Antibody SWOT Analysis
11.5.9 Thermo Fisher Scientific Recent Developments
11.6 Biorbyt
11.6.1 Biorbyt Corporation Information
11.6.2 Biorbyt Business Overview
11.6.3 Biorbyt Anti-CD47 Antibody Product Features and Attributes
11.6.4 Biorbyt Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.6.5 Biorbyt Recent Developments
11.7 Abbexa
11.7.1 Abbexa Corporation Information
11.7.2 Abbexa Business Overview
11.7.3 Abbexa Anti-CD47 Antibody Product Features and Attributes
11.7.4 Abbexa Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.7.5 Abbexa Recent Developments
11.8 Bio X Cell
11.8.1 Bio X Cell Corporation Information
11.8.2 Bio X Cell Business Overview
11.8.3 Bio X Cell Anti-CD47 Antibody Product Features and Attributes
11.8.4 Bio X Cell Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.8.5 Bio X Cell Recent Developments
11.9 GeneTex
11.9.1 GeneTex Corporation Information
11.9.2 GeneTex Business Overview
11.9.3 GeneTex Anti-CD47 Antibody Product Features and Attributes
11.9.4 GeneTex Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.9.5 GeneTex Recent Developments
11.10 R&D Systems
11.10.1 R&D Systems Corporation Information
11.10.2 R&D Systems Business Overview
11.10.3 R&D Systems Anti-CD47 Antibody Product Features and Attributes
11.10.4 R&D Systems Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 LSBio
11.11.1 LSBio Corporation Information
11.11.2 LSBio Business Overview
11.11.3 LSBio Anti-CD47 Antibody Product Features and Attributes
11.11.4 LSBio Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.11.5 LSBio Recent Developments
11.12 MyBioSource
11.12.1 MyBioSource Corporation Information
11.12.2 MyBioSource Business Overview
11.12.3 MyBioSource Anti-CD47 Antibody Product Features and Attributes
11.12.4 MyBioSource Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.12.5 MyBioSource Recent Developments
11.13 ProSci
11.13.1 ProSci Corporation Information
11.13.2 ProSci Business Overview
11.13.3 ProSci Anti-CD47 Antibody Product Features and Attributes
11.13.4 ProSci Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.13.5 ProSci Recent Developments
11.14 antibodies-online
11.14.1 antibodies-online Corporation Information
11.14.2 antibodies-online Business Overview
11.14.3 antibodies-online Anti-CD47 Antibody Product Features and Attributes
11.14.4 antibodies-online Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.14.5 antibodies-online Recent Developments
11.15 ABclonal Technology
11.15.1 ABclonal Technology Corporation Information
11.15.2 ABclonal Technology Business Overview
11.15.3 ABclonal Technology Anti-CD47 Antibody Product Features and Attributes
11.15.4 ABclonal Technology Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.15.5 ABclonal Technology Recent Developments
11.16 Abnova Corporation
11.16.1 Abnova Corporation Corporation Information
11.16.2 Abnova Corporation Business Overview
11.16.3 Abnova Corporation Anti-CD47 Antibody Product Features and Attributes
11.16.4 Abnova Corporation Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.16.5 Abnova Corporation Recent Developments
11.17 G Biosciences
11.17.1 G Biosciences Corporation Information
11.17.2 G Biosciences Business Overview
11.17.3 G Biosciences Anti-CD47 Antibody Product Features and Attributes
11.17.4 G Biosciences Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.17.5 G Biosciences Recent Developments
11.18 BioLegend
11.18.1 BioLegend Corporation Information
11.18.2 BioLegend Business Overview
11.18.3 BioLegend Anti-CD47 Antibody Product Features and Attributes
11.18.4 BioLegend Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.18.5 BioLegend Recent Developments
11.19 Bio-Rad
11.19.1 Bio-Rad Corporation Information
11.19.2 Bio-Rad Business Overview
11.19.3 Bio-Rad Anti-CD47 Antibody Product Features and Attributes
11.19.4 Bio-Rad Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.19.5 Bio-Rad Recent Developments
11.20 Huabio
11.20.1 Huabio Corporation Information
11.20.2 Huabio Business Overview
11.20.3 Huabio Anti-CD47 Antibody Product Features and Attributes
11.20.4 Huabio Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.20.5 Huabio Recent Developments
11.21 BPS Bioscience
11.21.1 BPS Bioscience Corporation Information
11.21.2 BPS Bioscience Business Overview
11.21.3 BPS Bioscience Anti-CD47 Antibody Product Features and Attributes
11.21.4 BPS Bioscience Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.21.5 BPS Bioscience Recent Developments
11.22 OriGene Technologies
11.22.1 OriGene Technologies Corporation Information
11.22.2 OriGene Technologies Business Overview
11.22.3 OriGene Technologies Anti-CD47 Antibody Product Features and Attributes
11.22.4 OriGene Technologies Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.22.5 OriGene Technologies Recent Developments
11.23 St John's Laboratory
11.23.1 St John's Laboratory Corporation Information
11.23.2 St John's Laboratory Business Overview
11.23.3 St John's Laboratory Anti-CD47 Antibody Product Features and Attributes
11.23.4 St John's Laboratory Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.23.5 St John's Laboratory Recent Developments
11.24 Absolute Antibody
11.24.1 Absolute Antibody Corporation Information
11.24.2 Absolute Antibody Business Overview
11.24.3 Absolute Antibody Anti-CD47 Antibody Product Features and Attributes
11.24.4 Absolute Antibody Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.24.5 Absolute Antibody Recent Developments
11.25 NSJ Bioreagents
11.25.1 NSJ Bioreagents Corporation Information
11.25.2 NSJ Bioreagents Business Overview
11.25.3 NSJ Bioreagents Anti-CD47 Antibody Product Features and Attributes
11.25.4 NSJ Bioreagents Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.25.5 NSJ Bioreagents Recent Developments
11.26 Cell Signaling Technology
11.26.1 Cell Signaling Technology Corporation Information
11.26.2 Cell Signaling Technology Business Overview
11.26.3 Cell Signaling Technology Anti-CD47 Antibody Product Features and Attributes
11.26.4 Cell Signaling Technology Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.26.5 Cell Signaling Technology Recent Developments
11.27 RayBiotech
11.27.1 RayBiotech Corporation Information
11.27.2 RayBiotech Business Overview
11.27.3 RayBiotech Anti-CD47 Antibody Product Features and Attributes
11.27.4 RayBiotech Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.27.5 RayBiotech Recent Developments
11.28 Beijing Solarbio Science & Technology
11.28.1 Beijing Solarbio Science & Technology Corporation Information
11.28.2 Beijing Solarbio Science & Technology Business Overview
11.28.3 Beijing Solarbio Science & Technology Anti-CD47 Antibody Product Features and Attributes
11.28.4 Beijing Solarbio Science & Technology Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.28.5 Beijing Solarbio Science & Technology Recent Developments
11.29 Bethyl Laboratories
11.29.1 Bethyl Laboratories Corporation Information
11.29.2 Bethyl Laboratories Business Overview
11.29.3 Bethyl Laboratories Anti-CD47 Antibody Product Features and Attributes
11.29.4 Bethyl Laboratories Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.29.5 Bethyl Laboratories Recent Developments
11.30 Abeomics
11.30.1 Abeomics Corporation Information
11.30.2 Abeomics Business Overview
11.30.3 Abeomics Anti-CD47 Antibody Product Features and Attributes
11.30.4 Abeomics Anti-CD47 Antibody Revenue and Gross Margin (2020-2025)
11.30.5 Abeomics Recent Developments
12 Anti-CD47 AntibodyIndustry Chain Analysis
12.1 Anti-CD47 Antibody Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-CD47 Antibody Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-CD47 Antibody Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Anti-CD47 Antibody Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Anti-CD47 Antibody Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Anti-CD47 Antibody Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Anti-CD47 Antibody Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Anti-CD47 Antibody Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Anti-CD47 Antibody Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Anti-CD47 Antibody by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-CD47 Antibody as of 2024)
Table 11. Global Anti-CD47 Antibody Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Anti-CD47 Antibody Companies Headquarters
Table 13. Global Anti-CD47 Antibody Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Anti-CD47 Antibody Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Anti-CD47 Antibody Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Anti-CD47 Antibody Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Anti-CD47 Antibody Revenue by Application (2026-2031) & (US$ Million)
Table 21. Anti-CD47 Antibody High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Anti-CD47 Antibody Growth Accelerators and Market Barriers
Table 25. North America Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Anti-CD47 Antibody Growth Accelerators and Market Barriers
Table 27. Europe Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Anti-CD47 Antibody Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Anti-CD47 Antibody Investment Opportunities and Key Challenges
Table 31. Central and South America Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Anti-CD47 Antibody Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Anti-CD47 Antibody Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. BosterBio Corporation Information
Table 35. BosterBio Description and Major Businesses
Table 36. BosterBio Product Features and Attributes
Table 37. BosterBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. BosterBio Revenue Proportion by Product in 2024
Table 39. BosterBio Revenue Proportion by Application in 2024
Table 40. BosterBio Revenue Proportion by Geographic Area in 2024
Table 41. BosterBio Anti-CD47 Antibody SWOT Analysis
Table 42. BosterBio Recent Developments
Table 43. Leinco Technologies Corporation Information
Table 44. Leinco Technologies Description and Major Businesses
Table 45. Leinco Technologies Product Features and Attributes
Table 46. Leinco Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Leinco Technologies Revenue Proportion by Product in 2024
Table 48. Leinco Technologies Revenue Proportion by Application in 2024
Table 49. Leinco Technologies Revenue Proportion by Geographic Area in 2024
Table 50. Leinco Technologies Anti-CD47 Antibody SWOT Analysis
Table 51. Leinco Technologies Recent Developments
Table 52. Bioss Corporation Information
Table 53. Bioss Description and Major Businesses
Table 54. Bioss Product Features and Attributes
Table 55. Bioss Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Bioss Revenue Proportion by Product in 2024
Table 57. Bioss Revenue Proportion by Application in 2024
Table 58. Bioss Revenue Proportion by Geographic Area in 2024
Table 59. Bioss Anti-CD47 Antibody SWOT Analysis
Table 60. Bioss Recent Developments
Table 61. Novus Biologicals Corporation Information
Table 62. Novus Biologicals Description and Major Businesses
Table 63. Novus Biologicals Product Features and Attributes
Table 64. Novus Biologicals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Novus Biologicals Revenue Proportion by Product in 2024
Table 66. Novus Biologicals Revenue Proportion by Application in 2024
Table 67. Novus Biologicals Revenue Proportion by Geographic Area in 2024
Table 68. Novus Biologicals Anti-CD47 Antibody SWOT Analysis
Table 69. Novus Biologicals Recent Developments
Table 70. Thermo Fisher Scientific Corporation Information
Table 71. Thermo Fisher Scientific Description and Major Businesses
Table 72. Thermo Fisher Scientific Product Features and Attributes
Table 73. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 75. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 76. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 77. Thermo Fisher Scientific Anti-CD47 Antibody SWOT Analysis
Table 78. Thermo Fisher Scientific Recent Developments
Table 79. Biorbyt Corporation Information
Table 80. Biorbyt Description and Major Businesses
Table 81. Biorbyt Product Features and Attributes
Table 82. Biorbyt Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Biorbyt Recent Developments
Table 84. Abbexa Corporation Information
Table 85. Abbexa Description and Major Businesses
Table 86. Abbexa Product Features and Attributes
Table 87. Abbexa Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Abbexa Recent Developments
Table 89. Bio X Cell Corporation Information
Table 90. Bio X Cell Description and Major Businesses
Table 91. Bio X Cell Product Features and Attributes
Table 92. Bio X Cell Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Bio X Cell Recent Developments
Table 94. GeneTex Corporation Information
Table 95. GeneTex Description and Major Businesses
Table 96. GeneTex Product Features and Attributes
Table 97. GeneTex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. GeneTex Recent Developments
Table 99. R&D Systems Corporation Information
Table 100. R&D Systems Description and Major Businesses
Table 101. R&D Systems Product Features and Attributes
Table 102. R&D Systems Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. R&D Systems Recent Developments
Table 104. LSBio Corporation Information
Table 105. LSBio Description and Major Businesses
Table 106. LSBio Product Features and Attributes
Table 107. LSBio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. LSBio Recent Developments
Table 109. MyBioSource Corporation Information
Table 110. MyBioSource Description and Major Businesses
Table 111. MyBioSource Product Features and Attributes
Table 112. MyBioSource Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. MyBioSource Recent Developments
Table 114. ProSci Corporation Information
Table 115. ProSci Description and Major Businesses
Table 116. ProSci Product Features and Attributes
Table 117. ProSci Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. ProSci Recent Developments
Table 119. antibodies-online Corporation Information
Table 120. antibodies-online Description and Major Businesses
Table 121. antibodies-online Product Features and Attributes
Table 122. antibodies-online Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. antibodies-online Recent Developments
Table 124. ABclonal Technology Corporation Information
Table 125. ABclonal Technology Description and Major Businesses
Table 126. ABclonal Technology Product Features and Attributes
Table 127. ABclonal Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. ABclonal Technology Recent Developments
Table 129. Abnova Corporation Corporation Information
Table 130. Abnova Corporation Description and Major Businesses
Table 131. Abnova Corporation Product Features and Attributes
Table 132. Abnova Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Abnova Corporation Recent Developments
Table 134. G Biosciences Corporation Information
Table 135. G Biosciences Description and Major Businesses
Table 136. G Biosciences Product Features and Attributes
Table 137. G Biosciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. G Biosciences Recent Developments
Table 139. BioLegend Corporation Information
Table 140. BioLegend Description and Major Businesses
Table 141. BioLegend Product Features and Attributes
Table 142. BioLegend Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. BioLegend Recent Developments
Table 144. Bio-Rad Corporation Information
Table 145. Bio-Rad Description and Major Businesses
Table 146. Bio-Rad Product Features and Attributes
Table 147. Bio-Rad Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Bio-Rad Recent Developments
Table 149. Huabio Corporation Information
Table 150. Huabio Description and Major Businesses
Table 151. Huabio Product Features and Attributes
Table 152. Huabio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Huabio Recent Developments
Table 154. BPS Bioscience Corporation Information
Table 155. BPS Bioscience Description and Major Businesses
Table 156. BPS Bioscience Product Features and Attributes
Table 157. BPS Bioscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 158. BPS Bioscience Recent Developments
Table 159. OriGene Technologies Corporation Information
Table 160. OriGene Technologies Description and Major Businesses
Table 161. OriGene Technologies Product Features and Attributes
Table 162. OriGene Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 163. OriGene Technologies Recent Developments
Table 164. St John's Laboratory Corporation Information
Table 165. St John's Laboratory Description and Major Businesses
Table 166. St John's Laboratory Product Features and Attributes
Table 167. St John's Laboratory Revenue (US$ Million) and Gross Margin (2020-2025)
Table 168. St John's Laboratory Recent Developments
Table 169. Absolute Antibody Corporation Information
Table 170. Absolute Antibody Description and Major Businesses
Table 171. Absolute Antibody Product Features and Attributes
Table 172. Absolute Antibody Revenue (US$ Million) and Gross Margin (2020-2025)
Table 173. Absolute Antibody Recent Developments
Table 174. NSJ Bioreagents Corporation Information
Table 175. NSJ Bioreagents Description and Major Businesses
Table 176. NSJ Bioreagents Product Features and Attributes
Table 177. NSJ Bioreagents Revenue (US$ Million) and Gross Margin (2020-2025)
Table 178. NSJ Bioreagents Recent Developments
Table 179. Cell Signaling Technology Corporation Information
Table 180. Cell Signaling Technology Description and Major Businesses
Table 181. Cell Signaling Technology Product Features and Attributes
Table 182. Cell Signaling Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 183. Cell Signaling Technology Recent Developments
Table 184. RayBiotech Corporation Information
Table 185. RayBiotech Description and Major Businesses
Table 186. RayBiotech Product Features and Attributes
Table 187. RayBiotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 188. RayBiotech Recent Developments
Table 189. Beijing Solarbio Science & Technology Corporation Information
Table 190. Beijing Solarbio Science & Technology Description and Major Businesses
Table 191. Beijing Solarbio Science & Technology Product Features and Attributes
Table 192. Beijing Solarbio Science & Technology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 193. Beijing Solarbio Science & Technology Recent Developments
Table 194. Bethyl Laboratories Corporation Information
Table 195. Bethyl Laboratories Description and Major Businesses
Table 196. Bethyl Laboratories Product Features and Attributes
Table 197. Bethyl Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 198. Bethyl Laboratories Recent Developments
Table 199. Abeomics Corporation Information
Table 200. Abeomics Description and Major Businesses
Table 201. Abeomics Product Features and Attributes
Table 202. Abeomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 203. Abeomics Recent Developments
Table 204. Raw Materials Key Suppliers
Table 205. Distributors List
Table 206. Market Trends and Market Evolution
Table 207. Market Drivers and Opportunities
Table 208. Market Challenges, Risks, and Restraints
Table 209. Research Programs/Design for This Report
Table 210. Key Data Information from Secondary Sources
Table 211. Key Data Information from Primary Sources


List of Figures
Figure 1. Anti-CD47 Antibody Product Picture
Figure 2. Global Anti-CD47 Antibody Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Monoclonal Antibody Product Picture
Figure 4. Polyclonal Antibody Product Picture
Figure 5. Global Anti-CD47 Antibody Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Biotechnology
Figure 7. Medical
Figure 8. University
Figure 9. Others
Figure 10. Anti-CD47 Antibody Report Years Considered
Figure 11. Global Anti-CD47 Antibody Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 13. Global Anti-CD47 Antibody Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Anti-CD47 Antibody Revenue Market Share by Region (2020-2031)
Figure 15. Global Anti-CD47 Antibody Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Monoclonal Antibody Revenue Market Share by Player in 2024
Figure 18. Polyclonal Antibody Revenue Market Share by Player in 2024
Figure 19. Global Anti-CD47 Antibody Revenue Market Share by Type (2020-2031)
Figure 20. Global Anti-CD47 Antibody Revenue Market Share by Application (2020-2031)
Figure 21. North America Anti-CD47 Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Anti-CD47 Antibody Revenue (US$ Million) in 2024
Figure 23. North America Anti-CD47 Antibody Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Anti-CD47 Antibody Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Anti-CD47 Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Anti-CD47 Antibody Revenue (US$ Million) in 2024
Figure 30. Europe Anti-CD47 Antibody Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Anti-CD47 Antibody Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 33. France Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Anti-CD47 Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Anti-CD47 Antibody Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Anti-CD47 Antibody Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Anti-CD47 Antibody Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 45. India Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Anti-CD47 Antibody Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Anti-CD47 Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Anti-CD47 Antibody Revenue (US$ Million) in 2024
Figure 53. Central and South America Anti-CD47 Antibody Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Anti-CD47 Antibody Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Anti-CD47 Antibody Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Anti-CD47 Antibody Revenue (US$ Million) in 2024
Figure 59. South America Anti-CD47 Antibody Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Anti-CD47 Antibody Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Anti-CD47 Antibody Revenue (2020-2025) & (US$ Million)
Figure 65. Anti-CD47 Antibody Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit